Page 2 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AstraZeneca s Lynparza meets primary endpoint in prostate cancer trial

AstraZeneca s Lynparza meets primary endpoint in prostate cancer trial
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.

Dayo laniyanSusan galbraithAlliance newsData monitoring committeeIndependent data monitoring committeeAll rightsசூசன் கல்பிரைத்கூட்டணி செய்திதகவல்கள் கண்காணிப்பு குழுசுயாதீனமான தகவல்கள் கண்காணிப்பு குழுஅனைத்தும் உரிமைகள்

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza PROpel trial meets primary endpoint

Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Lynparza PROpel trial meets primary endpoint
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United kingdomRoy baynesAdrian kempSusan galbraithCompany on twitterInternational journal of clinical practiceData monitoring committeeEastern cooperative oncology groupMerck co incResearch laboratoriesInvestor relations teamHead of global clinical developmentIndependent data monitoring committeeExecutive vice presidentSenior vice presidentGlobal clinical development

LONDON MARKET MIDDAY: Stocks fall as Evergrande silence sparks fear

LONDON MARKET MIDDAY: Stocks fall as Evergrande silence sparks fear
lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalHong kongUnited kingdomGulf of mexicoMexico generalRepublic ofCity ofNaeem aslamOxford nanoporeArvind bhunjunLondon stock exchangeAlliance newsService partners united kingdom ltdData monitoring committee

AstraZeneca plc (via Public) / Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer (Form 6-K)

AstraZeneca plc (via Public) / Lynparza in combination with abiraterone significantly delayed disease progression in all-comers in PROpel Phase III trial in 1st-line metastatic castration-resistant prostate cancer (Form 6-K)
publicnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from publicnow.com Daily Mail and Mail on Sunday newspapers.

United kingdomRoy baynesAdrian kempSusan galbraithInternational journal of clinical practiceData monitoring committeeEastern cooperative oncology groupMerck co incCompany on twitter astrazenecaResearch laboratoriesInvestor relations teamHead of global clinical developmentIndependent data monitoring committeeExecutive vice presidentSenior vice presidentGlobal clinical development

Lynparza® with abiraterone delays prostate cancer progression

Lynparza® with abiraterone delays prostate cancer progression
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

Susan galbraithData monitoring committeeIndependent data monitoring committeeExecutive vice presidentசூசன் கல்பிரைத்தகவல்கள் கண்காணிப்பு குழுசுயாதீனமான தகவல்கள் கண்காணிப்பு குழுநிர்வாகி துணை ப்ரெஸிடெஂட்